HC Wainwright Analysts Give IntelGenx Technologies (IGXT) a $2.00 Price Target
IntelGenx Technologies (OTCMKTS:IGXT) has been given a $2.00 price objective by stock analysts at HC Wainwright in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 193.17% from the stock’s current price.
Separately, ValuEngine cut IntelGenx Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd.
Shares of IntelGenx Technologies (OTCMKTS IGXT) remained flat at $$0.68 during mid-day trading on Wednesday. 45,642 shares of the stock traded hands, compared to its average volume of 77,336. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.65 and a quick ratio of 2.65. IntelGenx Technologies has a one year low of $0.62 and a one year high of $1.09.
IntelGenx Technologies Company Profile
IntelGenx Technologies Corp. is a drug delivery company focusing on the development of orally administered drug delivery products based on its oral drug delivery technologies. The Company is a provider of product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets.
Receive News & Ratings for IntelGenx Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies Corp. and related companies with MarketBeat.com's FREE daily email newsletter.